• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (4643608)   Today's Articles (38)   Subscriber (50572)
For: Masterson T, Patel P, Ramasamy R. Re: Limited success with clostridium collagenase histolyticum following FDA approval for the treatment of Peyronie's disease. Int J Impot Res 2019;32:251-252. [PMID: 30745568 DOI: 10.1038/s41443-019-0127-x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2018] [Accepted: 12/17/2018] [Indexed: 12/18/2022]
Number Cited by Other Article(s)
1
Collagenase Clostridium Histolyticum: A Review in Peyronie’s Disease. Clin Drug Investig 2019;40:83-92. [DOI: 10.1007/s40261-019-00867-5] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
2
Amighi A, Mills SA, Eleswarapu SV, Regets KV, Mendhiratta N, Mills JN. A modified technique for intralesional injection of collagenase Clostridium histolyticum for Peyronie’s disease results in reduced procedural morbidity using a standardized hematoma classification rubric. World J Urol 2019;38:293-298. [DOI: 10.1007/s00345-019-02812-9] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2019] [Accepted: 05/17/2019] [Indexed: 01/09/2023]  Open
PrevPage 1 of 1 1Next
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA